Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 10 of about 101 related to Herman: A clinical trial of continuous subcutaneous insulin infusion versus multiple daily.... (0.12 sec) 

A clinical trial of continuous subcutaneous insulin infusion versus multiple daily …


WH Herman, LL Ilag, SL Johnson, CL Martin, J … - Diabetes Care, 2005 - Am Diabetes Assoc
RESULTS—Forty-eight CSII subjects (91%) and 50 MDI subjects (93%) completed the
study. Mean A1C fell by 1.7 ± 1.0% in the CSII group to 6.6% and by 1.6 ± 1.2% in the MDI group
to 6.4%. The difference in A1C between treatment groups was not statistically significant ...
Cited by 85 - Related articles - BL Direct - All 5 versions

Insulin pump therapy vs. multiple daily injections in obese Type 2 diabetic patients


J Wainstein, M Metzger, M Boaz, O Minuchin, Y … - Diabetic …, 2005 - interscience.wiley.com
It is also possible that your web browser is not configured or not able to display style sheets.
In this case, although the visual presentation will be degraded, the site should continue to be
functional. We recommend using the latest version of Microsoft or Mozilla web browser to ...
Cited by 31 - Related articles - BL Direct - All 4 versions

Continuous subcutaneous insulin infusion and multiple daily injection therapy are …


P Raskin, BW Bode, JB Marks, IB Hirsch, RL Weinstein, … - Diabetes Care, 2003 - ncbi.nlm.nih.gov
OBJECTIVE: Compare the efficacy, safety, and patient satisfaction of continuous subcutaneous
insulin infusion (CSII) therapy with multiple daily injection (MDI) therapy for patients with type
2 diabetes. RESEARCH DESIGN AND METHODS: A total of 132 CSII-naive type 2 ...
Cited by 105 - Related articles - BL Direct - All 3 versions

Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple …

- diabetesjournals.org
IB Hirsch, BW Bode, S Garg, WS Lane, A Sussman, … - Diabetes Care, 2005 - Am Diabetes Assoc
RESULTS—Mean serum fructosamine levels were significantly lower after CSII therapy than
after MDI therapy (343 ± 47 vs. 355 ± 50 μmol/l, respectively; P = 0.0001). Continuous glucose
monitoring profiles over a 24-h time period showed that glucose exposure was 24 and ...
Cited by 45 - Related articles - All 7 versions

Continuous subcutaneous insulin infusion versus multiple daily injections: the …

- diabetesjournals.org [PDF] 
R Retnakaran, B Zinman - Diabetes Care, 2005 - Am Diabetes Assoc
Cardiac ventricles release B-type na- triuretic peptide (BNP) in response to volume expansion
and pressure overload; therefore, BNP concentration may be used as a biochemical marker
of cardiac failure (1). BNP levels are high in diabetic subjects with left ventricular dys- ...
Cited by 95 - Related articles - BL Direct - All 8 versions

Continuous subcutaneous insulin infusion with short-acting insulin analogues or …


RP Radermecker, AJ Scheen - Diabetes/Metabolism Reviews - interscience.wiley.com
Portable insulin infusion devices are effective and safe insulin delivery systems for managing
diabetes mellitus, especially type 1 diabetes. Rapidly absorbed insulin analogues, such as insulin
lispro or insulin aspart, may offer an advantage over regular human insulin for insulin ...
Cited by 50 - Related articles - BL Direct - All 3 versions

A comparison of glycaemic variability in CSII vs. MDI treated type 1 diabetic …


B Simon, V Treat, C Marco, D Rosenberg, … - … Journal of Clinical …, 2008 - interscience.wiley.com
It is also possible that your web browser is not configured or not able to display style sheets.
In this case, although the visual presentation will be degraded, the site should continue to be
functional. We recommend using the latest version of Microsoft or Mozilla web browser to ...
Related articles - All 3 versions

A randomized, prospective trial comparing the efficacy of continuous subcutaneous …

- diabetesjournals.org
EA Doyle, MSN APRN, SA Weinzimer, AT Steffen, … - Diabetes Care, 2004 - Am Diabetes Assoc
RESULTS—While there was no significant change in the glargine group (HbA 1c 8.2% at baseline
vs. 8.1% at 16 weeks), youth randomized to CSII had a sharp reduction in HbA 1c levels, from
8.1 to 7.2% after 16 weeks of therapy (P < 0.02 vs. baseline and <0.05 vs. glargine ...
Cited by 171 - Related articles - BL Direct - All 9 versions

Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and …


RP Hoogma, PJ Hammond, R Gomis, D Kerr, … - Diabetic …, 2006 - interscience.wiley.com
It is also possible that your web browser is not configured or not able to display style sheets.
In this case, although the visual presentation will be degraded, the site should continue to be
functional. We recommend using the latest version of Microsoft or Mozilla web browser to ...
Cited by 59 - Related articles - BL Direct - All 5 versions

Continuous subcutaneous insulin infusion and multiple daily injection therapy are …


P Raskin, BW Bode, JB Marks, IB Hirsch, RL … - Diabetes Care, 2003 - Am Diabetes Assoc
RESULTS—HbA 1c values decreased similarly for both groups from baseline (8.2 ± 1.37% for
CSII, 8.0 ± 1.08% for MDI) to end of study (7.6 ± 1.22% for CSII, 7.5 ± 1.22% for MDI). The CSII
group showed a trend toward lower eight-point BG values at most time points (only ...
Cited by 32 - Related articles - All 6 versions


Result Page: 

1

2

3

4

5

6

7

8

9

10

Next


 


Go to Google Home - About Google - About Google Scholar

©2009 Google